Polycystic Kidney Disease Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
Condition: Autosomal Dominant Polycystic Kidney Interventions: Drug: AL01211 or Placebo (Part A); Drug: AL01211 or Placebo (Part B); Drug: AL01211 or Placebo (Part C) Sponsors: AceLink Therapeutics, Inc.; Novotech (Australia) Pty Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2021 Category: Research Source Type: clinical trials

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Condition: Autosomal Recessive Polycystic Kidney Disease (ARPKD) Intervention: Drug: Tolvaptan (OPC-41061) Sponsor: Otsuka Pharmaceutical Development& Commercialization, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2021 Category: Research Source Type: clinical trials